Shuttle Pharmaceuticals Holdings, Inc. SHPH
November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company
building an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai
platform (hereafter, "Molecule.ai" or the "platform") helps researchers explore the chemical space more efficiently,
evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. The platform
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $4.1M | $3.6M | $3.5M | $1.0M | $1.0M | — |
| SG&A | $5.7M | $1.4M | $1.0M | $473.7K | $36.5K | — |
| Total operating expenses | $11.9M | $7.7M | $5.9M | $2.3M | $1.7M | — |
| Operating income | -$11.9M | -$7.7M | -$5.9M | -$2.3M | -$1.7M | — |
| Interest expense | — | $100.0K | $100.0K | — | — | — |
| Pre-tax income | — | — | -$6.6M | -$5.0M | -$1.2M | — |
| Net income | -$11.7M | -$9.1M | -$6.6M | -$5.0M | -$1.2M | — |
| EPS, basic | -7.16 | -79.65 | -3.53 | -5.04 | -0.12 | — |
| EPS, diluted | -7.16 | -82.60 | -3.53 | -5.04 | — | — |
| Shares, diluted (wtd. avg.) | $1.6M | $115.5K | $1.9M | $1.3M | $9.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $334.0K | $1.9M | $2.6M | $8.4M | $504.7K | — |
| Short-term investments | — | — | $2.9M | — | — | — |
| Total current assets | $502.9K | $2.2M | $5.6M | $8.6M | $509.6K | — |
| Property, plant and equipment | $17.3K | $19.4K | $24.8K | $12.6K | $18.6K | — |
| Other intangibles | $9.8M | — | — | — | — | — |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M | $651.6K | — |
| Accounts payable | $1.5M | $596.6K | — | — | — | — |
| Total current liabilities | $8.0M | $1.5M | $1.0M | $975.7K | $2.2M | — |
| Long-term debt | — | — | — | — | $91.0K | — |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975.7K | $2.3M | — |
| Retained earnings | -$46.3M | -$34.6M | -$25.4M | -$18.8M | -$13.8M | — |
| Total equity | $2.3M | $709.2K | $4.1M | $7.7M | -$1.8M | -$1.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.5M | -$7.3M | -$5.6M | -$2.7M | -$300.3K | — |
| Depreciation and amortisation | — | $5.5K | $6.8K | $6.0K | $6.2K | — |
| Stock-based compensation | $933.0K | $259.7K | $182.0K | $237.5K | $910.1K | — |
| Capital expenditure | — | — | $19.0K | — | — | — |
| Investing cash flow | -$3.1M | $2.9M | -$2.8M | — | — | — |
| Financing cash flow | $11.0M | $3.8M | $2.6M | $10.6M | $687.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014131.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |